Perrigo Co plc (PRGO)
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
- Symbol
- PRGO
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $1.98B
- 52 week range
- 9.23 - 22.65
Valuation
- Share price
- $13.84 (close of 2026-09-23)
- P/E (TTM)
- -1.14x
- Price to book
- 0.79x
- Price to free cash flow
- 16.64x
- Enterprise value
- $4.88B
- Book value per share
- $18.14
Price performance
| Period | Change |
|---|
| 1 day | -2.05% |
| 5 days | +2.06% |
| 1 month | -2.88% |
| 3 months | +45.84% |
| 6 months | +44.62% |
| Year to date | -0.57% |
| 1 year | -34.44% |
| 3 years | -57.09% |
| 5 years | -67.64% |
| 10 years | -85.79% |
| All time | +19.00% |
Profitability and growth
- Return on equity
- -48.56%
- Return on invested capital
- -18.57%
- Return on assets
- -16.70%
- Return on capital employed
- -14.92%
- Gross margin
- 35.14%
- Net margin
- -33.51%
- EBITDA margin
- -18.45%
- Revenue growth
- -2.75%
- Net income growth
- -729.69%
- Free cash flow growth
- -40.68%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 6.01%
- Current ratio
- 2.32x
- Net debt to EBITDA
- -2.63x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $4.25B
- Cost of revenue
- $2.76B
- Gross profit
- $1.49B
- EBITDA
- $-784.70M
- Net income
- $-1.43B
- Earnings per share
- $-10.29
- Research and development
- $95.40M
- Shares outstanding
- 138.50M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $4.25B | $1.49B | $-1.43B | $-10.29 |
| 2024-12-31 | $4.37B | $1.54B | $-171.80M | $-1.25 |
| 2023-12-31 | $4.66B | $1.68B | $-12.70M | $-0.09 |
| 2022-12-31 | $4.45B | $1.46B | $-140.60M | $-1.04 |
| 2021-12-31 | $4.14B | $1.42B | $-68.90M | $-0.52 |
| 2020-12-31 | $4.09B | $1.49B | $-162.60M | $-1.20 |
| 2019-12-31 | $3.87B | $1.43B | $146.10M | $1.07 |
| 2018-12-31 | $4.73B | $1.83B | $131.00M | $0.95 |
| 2017-12-31 | $4.95B | $1.98B | $119.60M | $0.84 |
| 2016-12-31 | $5.28B | $2.05B | $-4.01B | $-28.01 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 35.14% | -33.51% | -48.56% | -18.57% |
| 2024-12-31 | 35.27% | -3.93% | -3.98% | 0.77% |
| 2023-12-31 | 36.09% | -0.27% | -0.27% | 1.88% |
| 2022-12-31 | 32.69% | -3.16% | -2.90% | 0.95% |
| 2021-12-31 | 34.22% | -1.66% | -1.34% | 2.93% |
| 2020-12-31 | 36.57% | -3.98% | -2.88% | 3.02% |
| 2019-12-31 | 37.05% | 3.78% | 2.52% | 1.95% |
| 2018-12-31 | 38.71% | 2.77% | 2.31% | 1.39% |
| 2017-12-31 | 40.02% | 2.42% | 1.94% | 4.96% |
| 2016-12-31 | 38.86% | -75.99% | -67.36% | -10.46% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $531.60M | $3.60B |
| 2024-12-31 | $558.80M | $3.58B |
| 2023-12-31 | $751.30M | $3.63B |
| 2022-12-31 | $600.70M | $4.07B |
| 2021-12-31 | $1.86B | $2.92B |
| 2020-12-31 | $631.50M | $3.53B |
| 2019-12-31 | $354.30M | $3.37B |
| 2018-12-31 | $551.10M | $3.05B |
| 2017-12-31 | $678.70M | $3.27B |
| 2016-12-31 | $622.30M | $5.22B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $145.10M | $54.60M |
| 2024-12-31 | $244.60M | $64.40M |
| 2023-12-31 | $303.80M | $68.80M |
| 2022-12-31 | $210.90M | $54.90M |
| 2021-12-31 | $4.20M | $60.10M |
| 2020-12-31 | $465.80M | $58.50M |
| 2019-12-31 | $250.10M | $52.20M |
| 2018-12-31 | $490.40M | $37.70M |
| 2017-12-31 | $610.30M | $43.80M |
| 2016-12-31 | $548.70M | $23.00M |
Dividend history
- Most recent payment
- 2026-08-28
- Paid in the last twelve months
- $0.87
| Payment date | Dividend per share |
|---|
| 2026-08-28 | $0.29 |
| 2026-05-29 | $0.29 |
| 2026-03-02 | $0.29 |
| 2025-08-29 | $0.29 |
| 2025-05-30 | $0.29 |
| 2025-03-07 | $0.29 |
| 2024-11-29 | $0.28 |
| 2024-08-30 | $0.28 |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-04
- Consensus EPS estimate
- $0.57
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-05 | Jun/2026 | $0.31 |
| 2026-05-06 | - | - |
| 2026-02-26 | - | - |
| 2025-11-05 | - | - |
| 2025-08-06 | - | - |
| 2025-05-07 | - | - |
| 2025-02-27 | - | - |
| 2024-11-06 | - | - |
Filings and sources
- Company website
- perrigo.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Zoetis Inc. (ZTS) · Viatris Inc (VTRS) · Hims & Hers Health, Inc. (HIMS) · Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades